Abstract

[LANGUAGE= "English"] INTRODUCTION: This study aimed to research the diversities of vitamin E and oxidative stress parameters related to sodiumglucose transport protein 2 (SGLT2) inhibitor use by type 2 diabetes mellitus (T2DM) patients.

METHODS: This observational clinical study collected data from 67 T2DM patients (55.7±9.3 years, 46% female). Vitamin E, total oxidant status (TOS), total antioxidant status (TAS), total thiol, native thiol, myeloperoxidase, and catalase levels were evaluated. The TOS/TAS ratio was calculated as the oxidative stress index. Correlations of the parameters to each other and differences based on SGLT2 inhibitor use were recorded.

RESULTS: The mean hemoglobin A1c was 7.1 (5.5–13.1). SGLT2 inhibitors (all combinations) were used by 25 patients (37.3%). The mean level of vitamin E was 6 (3.6–9.8) mg/L. There was a positive correlation between vitamin E and low-density lipoprotein cholesterol (p<0.001). While there was no significant correlation between vitamin E and all included oxidative stress parameters, the level of vitamin E was statistically lower in patients using pioglitazone (p=0.036) and statins (p<0.001). In patients using SGLT2 inhibitors, fasting glucose, triglycerides, alanine aminotransferase, and the spot urine protein/creatinine ratio were significantly lower, and the mean TAS was higher (p<0.05).

DISCUSSION AND CONCLUSION: While no differences were observed in vitamin E and other oxidative parameters related to SGLT2 inhibitor use, the increase in TAS provides motivation for further research investigating the antioxidant properties of these inhibitors.

Alternate abstract:

INTRODUCTION: This study aimed to research the diversities of vitamin E and oxidative stress parameters related to sodiumglucose transport protein 2 (SGLT2) inhibitor use by type 2 diabetes mellitus (T2DM) patients.

METHODS: This observational clinical study collected data from 67 T2DM patients (55.7±9.3 years, 46% female). Vitamin E, total oxidant status (TOS), total antioxidant status (TAS), total thiol, native thiol, myeloperoxidase, and catalase levels were evaluated. The TOS/TAS ratio was calculated as the oxidative stress index. Correlations of the parameters to each other and differences based on SGLT2 inhibitor use were recorded.

RESULTS: The mean hemoglobin A1c was 7.1 (5.5–13.1). SGLT2 inhibitors (all combinations) were used by 25 patients (37.3%). The mean level of vitamin E was 6 (3.6–9.8) mg/L. There was a positive correlation between vitamin E and low-density lipoprotein cholesterol (p<0.001). While there was no significant correlation between vitamin E and all included oxidative stress parameters, the level of vitamin E was statistically lower in patients using pioglitazone (p=0.036) and statins (p<0.001). In patients using SGLT2 inhibitors, fasting glucose, triglycerides, alanine aminotransferase, and the spot urine protein/creatinine ratio were significantly lower, and the mean TAS was higher (p<0.05).

DISCUSSION AND CONCLUSION: While no differences were observed in vitamin E and other oxidative parameters related to SGLT2 inhibitor use, the increase in TAS provides motivation for further research investigating the antioxidant properties of these inhibitors.

Details

Title
The changes of oxidative stress markers and vitamin E in patients with diabetes using SGLT2 inhibitors
Author
Buyukaydin, Banu  VIAFID ORCID Logo  ; Ozer, Omer Faruk  VIAFID ORCID Logo  ; Ozder, Aclan  VIAFID ORCID Logo  ; Yildiz, Caner  VIAFID ORCID Logo 
Pages
185-190
Section
RESEARCH ARTICLE
Publication year
2023
Publication date
2023
Publisher
Kare Publishing
ISSN
25872362
e-ISSN
2618642X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3095347064
Copyright
© 2023. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.